# Thymulin Dosage in Research: Doses by Species, Route, and Half-Life > Thymulin dosage reported in research studies — by species and route, never as human guidance. Includes the routes studied and what is known about thymulin half-life. Research-context only. What was administered, to which species, by which route — set down as the studies recorded it, and never as a protocol for a person. ## In plain English There is no established human dose of thymulin. It is a research peptide, not an approved medicine, so this page does not tell anyone what to take — it records what scientists gave to animals and cells, and by what route. The numbers below are small (nanograms to a few micrograms per animal) and they belong to specific experiments in mice, chickens, and rats. Read them as a catalogue of the literature, not as guidance. Thymulin dosage in research is reported per study; standardized human dosing does not exist in the public record. ## Thymulin dosage reported in research studies Reported thymulin doses sit in the nanogram-to-low-microgram range per animal, varying by model and route. Representative figures from the cited record: - **Mouse, LPS pancreatic-protection model:** 50 µg per animal, intraperitoneal, before the LPS challenge [13]. - **Mouse, virus-induced diabetes/myocarditis model:** 10-50 µg per animal, subcutaneous, before challenge [14]. - **Chicken, antiviral NK-cell model:** 10 ng and 50 ng per 100 g body weight, in vivo [15]. - **Mouse, systemic-inflammation model:** thymulin given daily for two weeks before LPS; the abstract reports the schedule rather than a numeric dose [6]. - **Rodent CNS / anti-inflammatory work:** nanogram-to-low-microgram amounts, including intracerebroventricular doses, per the review record [4]. Gene-therapy studies do not report a peptide dose at all — they deliver a single vector dose (adenoviral or nanoparticle-borne plasmid) engineered to produce thymulin over time, a strategy adopted specifically because the native peptide is short-lived [5][7]. None of these is a human dose, and none should be read as one. ## How thymulin is administered in research The routes studied span parenteral, central, pulmonary, and in-vitro delivery. Across the cited work these include intraperitoneal [13], subcutaneous [14], intracerebroventricular [4], intratracheal (for inhaled gene therapy) [7], intramuscular and intracerebral (for gene-therapy vectors) [5], topical (the zinc-thymulin alopecia pilot), and direct in-vitro incubation with cultured cells [8]. Human work is the sparse exception: early controlled and open trials used a synthetic analog (nonathymulin) and FTS-Zn, and a small open-label pilot studied a topical zinc-thymulin preparation. There is no approved human injectable thymulin product. ## What is the half-life of thymulin? ### What is the half-life of thymulin? Native thymulin is a small peptide with a short circulating half-life, and its precise human pharmacokinetic half-life is not well characterized in the public literature. The clearest evidence for the short-life problem is indirect but telling: the gene-therapy approaches were developed expressly to sustain circulating thymulin levels over time, which would be unnecessary if the native peptide persisted [5]. Treat any specific half-life figure with caution — the public record does not establish one for humans. ## Stability and the zinc requirement One stability fact dominates all dose considerations: activity requires the bound zinc ion. Zinc chelation — by EDTA or Chelex, for instance — abolishes activity, and the apopeptide remains inactive until zinc is restored [1][2]. Any reported thymulin effect is therefore an effect of the zinc-bound complex, and the zinc status of a system materially shapes the result. This is why the literature so often pairs thymulin findings with zinc measurements, and why thymulin-specific dose-response is hard to read cleanly apart from zinc. ## What is the dosage of thymulin peptide? ### What is the dosage of thymulin peptide? There is no established human dosage of thymulin peptide. It is a research peptide handled for laboratory use, and reported doses are study findings in animal models — nanogram-to-microgram ranges by route and species, as catalogued above — not protocols for people. Anyone encountering a specific human dosing schedule for thymulin should treat it as unsupported by the published record. --- A finely-kept specimen cabinet of the thymulin literature — the zinc-bound thymic nonapeptide catalogued from a thin, dated record, its established findings engraved beside its open gaps and the molecule held distinct from thymosin alpha-1 and thymalin; a heritage archive, not a clinic, a vendor, or a prescription.